TY - JOUR
T1 - Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma
T2 - an analysis of hospital data in the United States
AU - Maziarz, Richard T.
AU - Yang, Hongbo
AU - Liu, Qing
AU - Wang, Travis
AU - Zhao, Jing
AU - Lim, Stephen
AU - Lee, Soyon
AU - Dalal, Anand
AU - Bollu, Vamsi
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - This study compared the real-world healthcare resource utilization (HRU), costs, adverse events (AEs), and AE treatments associated with the chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel), for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Adults with DLBCL who received tisa-cel or axi-cel were identified in the Premier Healthcare Database (2017–2020). Non-CAR-T costs, HRU, and AE rates during the infusion and follow-up periods were compared between the tisa-cel and axi-cel cohorts. Of 119 patients, 33 received tisa-cel (86% as inpatient infusion) and 86 received axi-cel (100% inpatient). Tisa-cel was associated with significantly shorter mean inpatient length of stay than axi-cel during infusion (11.3 vs. 18.3 days) and follow-up ([monthly] 3.9 vs. 6.9 days). Non-CAR-T costs were significantly lower for tisa-cel compared with axi-cel during infusion ($27594.8 vs. $51378.3) and follow-up ([monthly] $28777.3 vs. $46575.7; both p<.05). Rates of AEs and AE treatments were similar.
AB - This study compared the real-world healthcare resource utilization (HRU), costs, adverse events (AEs), and AE treatments associated with the chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel), for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Adults with DLBCL who received tisa-cel or axi-cel were identified in the Premier Healthcare Database (2017–2020). Non-CAR-T costs, HRU, and AE rates during the infusion and follow-up periods were compared between the tisa-cel and axi-cel cohorts. Of 119 patients, 33 received tisa-cel (86% as inpatient infusion) and 86 received axi-cel (100% inpatient). Tisa-cel was associated with significantly shorter mean inpatient length of stay than axi-cel during infusion (11.3 vs. 18.3 days) and follow-up ([monthly] 3.9 vs. 6.9 days). Non-CAR-T costs were significantly lower for tisa-cel compared with axi-cel during infusion ($27594.8 vs. $51378.3) and follow-up ([monthly] $28777.3 vs. $46575.7; both p<.05). Rates of AEs and AE treatments were similar.
KW - Adverse events
KW - axicabtagene ciloleucel
KW - diffuse large B-cell lymphoma
KW - healthcare costs
KW - healthcare resource utilization
KW - tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85129158263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129158263&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2060503
DO - 10.1080/10428194.2022.2060503
M3 - Article
C2 - 35422192
AN - SCOPUS:85129158263
SN - 1042-8194
VL - 63
SP - 2052
EP - 2062
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -